Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000939
Chunk: 25

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 25
---
, any
(i) “short sale” (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of the Depositary Shares or (ii)
hedging transaction, which establishes a net short position with respect to the Depositary Shares.

(k) . The Investor is not purchasing or acquiring the Securities as a result of any form of general solicitation or
general advertising (within the meaning of Regulation D promulgated under the Securities Act) in connection with the offer or sale of
the Securities.

(l) . The Investor acknowledges that it will be disclosed as an “underwriter” and a “selling stockholder”
in the Registration Statement and in any Prospectus contained therein to the extent required by applicable law.

4. REPRESENTATIONS AND WARRANTIES OF THE COMPANY.

The Company represents and
warrants to the Investor that, except as set forth in the (i) SEC Documents or (ii) disclosure schedules attached hereto, which exceptions
shall be deemed to be a part of, and shall qualify, the representations and warranties made hereunder (the “”),
as of the Execution Date and as of the Commencement Date:

(a) . The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized, validly existing
and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite corporate power and authority
to own and use its properties and assets and to carry on its business as currently conducted. Each of the Company and its Subsidiaries
is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the
nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified
or in good standing, as the case may be, would not have or reasonably be expected to result in a Material Adverse Effect, and no proceeding
has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority
or qualification. The Company has no Subsidiaries required to be disclosed pursuant to Item 601(b)(21)(ii) of Regulation S-K, except as
set forth in the Company’s Annual Report on Form 20-F for its fiscal year ended December 31, 2023 filed with the SEC on April 19,
2024 (the “”).

| -12- |

(b) . (i) The Company has